This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.
You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/7049205.stm
The article has changed 2 times. There is an RSS feed of changes available.
Previous version
1
Next version
Version 0 | Version 1 |
---|---|
Promising results for malaria jab | Promising results for malaria jab |
(about 19 hours later) | |
Scientists and global health campaigners have welcomed the early results of a malaria vaccine trial in African infants. | Scientists and global health campaigners have welcomed the early results of a malaria vaccine trial in African infants. |
Tests showed the vaccine gave a high level of protection, and was safe | Tests showed the vaccine gave a high level of protection, and was safe |
The results, published online by the Lancet, appear to bring closer the prospect of a vaccine against one of the developing world's biggest killers. | The results, published online by the Lancet, appear to bring closer the prospect of a vaccine against one of the developing world's biggest killers. |
Every 30 seconds a child in Africa dies from malaria - around one million every year. | |
So an effective vaccine would have massive life-saving potential. | So an effective vaccine would have massive life-saving potential. |
We have plenty of vaccines against viruses and bacteria but this would be the first vaccine against a parasitic infection in humans Dr Joe CohenGlaxoSmithKline | We have plenty of vaccines against viruses and bacteria but this would be the first vaccine against a parasitic infection in humans Dr Joe CohenGlaxoSmithKline |
A prototype vaccine has been in development and trials for 20 years and now it has been tested in African babies - the most vulnerable of all age groups. | A prototype vaccine has been in development and trials for 20 years and now it has been tested in African babies - the most vulnerable of all age groups. |
The study, was small, involving 214 infants in Mozambique. Furthermore, these are early results, so caution is needed in interpreting the data. | The study, was small, involving 214 infants in Mozambique. Furthermore, these are early results, so caution is needed in interpreting the data. |
But crucially the vaccine was shown to be safe. | But crucially the vaccine was shown to be safe. |
But it also appears highly protective: after three months infants who'd received it were 65% less likely to contract malaria than a control group. | But it also appears highly protective: after three months infants who'd received it were 65% less likely to contract malaria than a control group. |
The quest for a vaccine represents a partnership between several African nations, the pharmaceutical industry and the PATH Malaria Vaccine Initiative (MVI). | The quest for a vaccine represents a partnership between several African nations, the pharmaceutical industry and the PATH Malaria Vaccine Initiative (MVI). |
Christian Loucq, director of MVI, said: "These results essentially provide another green light indicating that we can move toward a large Phase 3 trial with this vaccine." | Christian Loucq, director of MVI, said: "These results essentially provide another green light indicating that we can move toward a large Phase 3 trial with this vaccine." |
That trial will begin next year in ten sites across sub-Saharan Africa and involve 10,000 thousand children. | That trial will begin next year in ten sites across sub-Saharan Africa and involve 10,000 thousand children. |
If successful the vaccine will be licensed in 2011. | If successful the vaccine will be licensed in 2011. |
It would mark a hugely significant step forward in the fight against malaria. | It would mark a hugely significant step forward in the fight against malaria. |
Huge challenge | Huge challenge |
Dr Joe Cohen, from GlaxoSmithKline, has spent 20 years on the project. | Dr Joe Cohen, from GlaxoSmithKline, has spent 20 years on the project. |
He said: "Creating a malaria vaccine has been a huge challenge because of the complexity of the disease. | He said: "Creating a malaria vaccine has been a huge challenge because of the complexity of the disease. |
"We have plenty of vaccines against viruses and bacteria but this would be the first vaccine against a parasitic infection in humans." | "We have plenty of vaccines against viruses and bacteria but this would be the first vaccine against a parasitic infection in humans." |
The Microsoft billionaire Bill Gates has given hundreds of millions of dollars to malaria vaccine and treatment programmes. | |
He called on global leaders to embrace "an audacious goal - to reach a day when no human being has malaria, and no mosquito on earth is carrying it." | He called on global leaders to embrace "an audacious goal - to reach a day when no human being has malaria, and no mosquito on earth is carrying it." |
He was speaking in Seattle to a meeting of 300 scientists and policymakers. | He was speaking in Seattle to a meeting of 300 scientists and policymakers. |
"We have a real chance to build the partnerships, generate the political will, and develop the scientific breakthroughs we need to end this disease," he said. | "We have a real chance to build the partnerships, generate the political will, and develop the scientific breakthroughs we need to end this disease," he said. |
"We will not stop working until malaria is eradicated." | "We will not stop working until malaria is eradicated." |
Previous version
1
Next version